日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The role of ventilatory support for long-term outcomes after critical infection with COVID-19: A prospective cohort study

呼吸机支持在新冠肺炎重症感染后长期预后中的作用:一项前瞻性队列研究

Hanna, Gabriel; Bankler, Sara; Schandl, Anna; Roël, Mari; Hedman, Anders; Andersson Franko, Mikael; Lyngå, Patrik; Geborek, Anne; Joelsson-Alm, Eva; Söderberg, Mårten; Darlington, Pernilla

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment

未接受疾病修饰治疗的类风湿性关节炎或原发性干燥综合征患者,对13价肺炎球菌结合疫苗的抗体反应不受影响。

Nived, Per; Saxne, Tore; Geborek, Pierre; Mandl, Thomas; Skattum, Lillemor; Kapetanovic, Meliha C

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies

利妥昔单抗在临床实践中的应用:剂量、药物依从性、免疫球蛋白水平、感染和药物抗体

Einarsson, Jon Thorkell; Evert, Max; Geborek, Pierre; Saxne, Tore; Lundgren, Maria; Kapetanovic, Meliha C

EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry

EQ-5D效用值、疗效和药物生存率在接受生物制剂单药治疗的类风湿关节炎患者中的评估:一项基于瑞典南部SSATG注册登记患者的前瞻性观察研究

Jørgensen, Tanja Schjødt; Turesson, Carl; Kapetanovic, Meliha; Englund, Martin; Turkiewicz, Aleksandra; Christensen, Robin; Bliddal, Henning; Geborek, Pierre; Kristensen, Lars Erik

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial

抗瓜氨酸化肽抗体反应的变化与早期类风湿性关节炎的治疗结果相关:SWEFOT试验的结果

Kastbom, Alf; Forslind, Kristina; Ernestam, Sofia; Geborek, Pierre; Karlsson, Johan A; Petersson, Ingemar F; Saevarsdottir, Saedis; Klareskog, Lars; van Vollenhoven, Ronald F; Lundberg, Karin

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis

肿瘤坏死因子-α与依那西普之间的循环复合物可预测依那西普治疗幼年特发性关节炎的长期疗效

Kahn, Robin; Berthold, Elisabet; Gullstrand, Birgitta; Schmidt, Tobias; Kahn, Fredrik; Geborek, Pierre; Saxne, Tore; Bengtsson, Anders A; Månsson, Bengt

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

英夫利昔单抗与常规联合治疗在甲氨蝶呤难治性早期类风湿关节炎中的成本效益:基于注册登记数据的随机对照SWEFOT试验的2年结果

Eriksson, Jonas K; Karlsson, Johan A; Bratt, Johan; Petersson, Ingemar F; van Vollenhoven, Ronald F; Ernestam, Sofia; Geborek, Pierre; Neovius, Martin

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

早期类风湿关节炎患者的治疗前多生物标志物疾病活动评分与放射学进展:SWEFOT试验结果

Hambardzumyan, Karen; Bolce, Rebecca; Saevarsdottir, Saedis; Cruickshank, Scott E; Sasso, Eric H; Chernoff, David; Forslind, Kristina; Petersson, Ingemar F; Geborek, Pierre; van Vollenhoven, Ronald F

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial

吸烟状况是早期类风湿性关节炎放射学进展的强预测因子:SWEFOT试验结果

Saevarsdottir, Saedis; Rezaei, Hamed; Geborek, Pierre; Petersson, Ingemar; Ernestam, Sofia; Albertsson, Kristina; Forslind, Kristina; van Vollenhoven, Ronald F

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion

简报:以多生物标志物疾病活动评分作为纳入标准,提高类风湿性关节炎临床试验的患者招募率

van Vollenhoven, Ronald F; Bolce, Rebecca; Hambardzumyan, Karen; Saevarsdottir, Saedis; Forslind, Kristina; Petersson, Ingemar F; Sasso, Eric H; Hwang, C C; Segurado, Oscar G; Geborek, Pierre